Medical Research

ALZHEIMER'S DRUG DISCOVERY FOUNDATION

aka ADDF   |   NEW YORK, NY   |  www.alzdiscovery.org

Mission

ACCELERATE THE DISCOVERY AND DEVELOPMENT OF DRUGS TO PREVENT, TREAT AND CURE ALZHEIMER'S DISEASE, RELATED DEMENTIAS AND COGNITIVE AGING

Ruling year info

2005

Founding Executive Director and Chief Science Officer

Howard Fillit MD

Main address

57 W. 57th St. Suite 904

NEW YORK, NY 10019 USA

Show more addresses

Formerly known as

Institute for the Study of Aging

EIN

20-1082179

Cause area (NTEE code) info

Alzheimer's (H83)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2018, 2017 and 2016.
Register now

Communication

Programs and results

What we aim to solve

This profile needs more info.

If it is your nonprofit, add a problem overview.

Login and update

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Drug Discovery

The ADDF is focused on translational research—translating the knowledge we have gained about the underlying causes of Alzheimer's disease into drugs. We fund programs in academia and biotechnology companies worldwide, with priority funding in drug development, clinical trials, biomarkers, and prevention.

Population(s) Served
Aging, elderly, senior citizens

ADDF Access provides academic and small biotechnology researchers with access to a virtual network of contract research organizations, drug development experts and educational resources.

Population(s) Served
Adults

The ADDF's Aging and Alzheimer's Prevention program provides an independent scientific evaluation of the evidence surrounding pharmaceuticals, supplements and natural products that claim to prevent or delay cognitive aging and Alzheimer's. The program also works to enhance innovative approaches to strengthen the evidence for prevention through targeted funding.

Population(s) Served
Adults

Where we work

Our results

SOURCE: Self-reported by organization

How does this organization measure their results? It's a hard question but an important one.

Total dollar amount of grants awarded

This metric is no longer tracked.
Totals By Year
Related Program

Drug Discovery

Total number of grants awarded

This metric is no longer tracked.
Totals By Year
Related Program

Drug Discovery

Number of organizational partners

This metric is no longer tracked.
Totals By Year

Number of organizations applying for grants

This metric is no longer tracked.
Totals By Year

Charting impact

SOURCE: Self-reported by organization

Five powerful questions that require reflection about what really matters - results.

What is the organization aiming to accomplish?

We aim to support the most promising, novel Alzheimer's drug discovery research--from drug target validation through early-phase clinical trials--to find an effective treatment, and cure, for Alzheimer's disease and related dementias.

We regularly seek and promote requests for proposals from researchers around the world; evaluate the promise of these proposals with our team of neuroscientists and our independent, renowned Scientific Review Board; and invest in the research that our team has deemed the most promising.

We have a highly regarded science team led by Howard Fillit, MD, a leader in geriatric medicine, and a supporting staff of four PhD neuroscientists. Additionally, our Scientific Review Board provides outside, independent evaluation of the quality of the grant proposals we receive and make recommendations for funding. <br/><br/>In 2013, we invested more than $8 million in the drug discovery research recommended by this team.

We know that we are making progress when our investments are returned to us and reinvested in further drug discovery research, when our grantees receive follow-on funding for their research, and when our grantees' research makes it to the next stage of drug discovery and development.<br/><br/>From more than $15.7 million invested in biotechnology programs, $3.6 million has been returned to date and immediately reinvested in new drug research programs. Subsequent to the ADDF's initial funding, our grantees have received commitments of over $2 billion in follow-on funding from government, pharmaceutical companies and venture capital firms to further advance their drug research. And to date, 38 programs in which we have invested have made it to the clinical trial stage.

Though we do not yet have an FDA-approved, disease-modifying treatment for Alzheimer's disease or a related dementia, we have made significant progress. In 2012, the US Food and Drug Administration (FDA) approved Amyvid™, the first diagnostic test for Alzheimer's disease. The ADDF seed-funded the research for Amyvid™ from 2000–2004. Amyvid™ is improving and accelerating clinical trials for by ensuring that all patients enrolled have Alzheimer's disease. <br/><br/>Of the nearly 500 programs in which we've invested, 38 have advanced to the clinical trial stage and more than 20 of those are ongoing. Programs we have funded represent approximately 20% of all treatments currently in clinical trials for Alzheimer's (using October 2015 data from clinicaltrials.gov and Alzforum.org).

Financials

ALZHEIMER'S DRUG DISCOVERY FOUNDATION
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

This organization has no recorded board members.

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? No
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? No

Keywords

drug discovery, Alzhemer's, research